FMC (FMC) Earnings Date & Reports

Key Takeaways

• FMC Corporation reported third quarter 2026 revenue of $106 million, an 80% decline year over year that came in far below Wall Street expectations.
• The company posted a GAAP (generally accepted accounting principles) net loss of $2.07 billion, or $15.54 per diluted share, versus a $569 million loss in the prior-year period.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) swung to negative $559 million, weighed down by a $672 million impact from intentional commercial actions.
• A $639 million revenue impact from commercial actions, combined with weaker-than-expected demand, drove the quarterly shortfall.
• Fourth quarter 2026 revenue guidance was set at $1.04 billion to $1.14 billion, with the midpoint roughly flat versus the fourth quarter of 2025.
• Management said its priority is now "disciplined execution with our customers" as it works through its post-patent and portfolio transformation.
• For more context on this ticker, explore FMC's Major News, Today's Price Move, Price Targets, and Forecast on dedicated analysis pages.
• Interested in broader market opportunities? Explore Trending AI Robots to see automated strategies currently drawing attention from traders.

Earnings Context and Why It Matters

FMC Corporation is an agricultural sciences company whose crop protection portfolio has been undergoing a difficult transition as its flagship Rynaxypyr® active ingredient moves past patent protection and as the company executes a series of strategic divestitures. Those efforts, including the planned sale of its India commercial business and other asset monetizations aimed at debt reduction, have produced substantial non-cash charges and disrupted near-term revenue. For investors, this report matters because it tests whether management's restructuring can stabilize the business and return it to growth. The quarter's massive top-line shortfall and deepening losses signal that the transition is proving more painful than anticipated, raising fresh questions about cash generation and the balance sheet.

Reported Results

FMC reported third quarter 2026 revenue of $106 million, down 80% from $542 million a year earlier and dramatically below analyst consensus. Management attributed the decline primarily to a $639 million revenue impact from commercial actions, alongside weaker-than-expected customer demand.

On a GAAP basis, the company recorded a net loss of $2.07 billion, or $15.54 per diluted share, compared with a loss of $569 million, or $4.52 per share, in the third quarter of 2025. Adjusted EBITDA fell to negative $559 million from positive $236 million a year ago, reflecting a $672 million negative impact from commercial actions.

Free cash flow was negative $18 million, an improvement of $214 million year over year, driven by favorable working capital dynamics despite cash outflows for restructuring. For the fourth quarter, FMC guided to revenue of $1.04 billion to $1.14 billion, with a midpoint roughly stable compared with the prior-year period.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing potential setups that might otherwise be missed. Explore the AI Screener to put these capabilities to work in your own research process.

Market Reaction and Investor Sentiment

Sentiment around FMC has deteriorated sharply over the past year as the post-patent transition and restructuring charges have eroded earnings. The stock has already fallen steeply in 2026, and this quarter's results — which missed estimates by a wide margin — reinforced investor concerns about demand and execution. Elevated short interest signals that a meaningful portion of the market remains positioned for further downside, while the combination of heavy non-cash charges and negative adjusted EBITDA underscores the pressure on profitability. The weak quarter, paired with a full-year outlook revised lower, suggests the market is likely to remain cautious until FMC demonstrates sustained stabilization in revenue and cash flow.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether FMC can deliver the fourth quarter revenue recovery embedded in its guidance of $1.04 billion to $1.14 billion. Management expects volume growth to return, helped by increased direct sales to growers in Brazil, new active ingredients, and North America distributor orders that shifted from the third quarter into the fourth.

Key factors to monitor include the progress of the Rynaxypyr® post-patent strategy and whether pricing stabilizes after the planned commercial actions. The completion of asset sales — including the India divestiture and other monetizations intended to fund roughly $1 billion in debt reduction — will be critical for the balance sheet.

Investors should also watch free cash flow trends, interest expense, and any further restructuring costs, as these will determine how quickly FMC can return to profitability. Demand signals across agricultural end markets and distributor inventory behavior will remain important swing factors in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations